Stellate Ganglion Block in Preventing Cerebral Vasospasm Secondary to Subarachnoid Hemorrhage

Effect of Stellate Ganglion Block on Cerebral Vasospasm in Patients With Emergency Aneurysmal Subarachnoid Hemorrhage

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04512859

Enrollment

160

Registered

2020-08-14

Start date

2020-09-01

Completion date

2022-12-31

Last updated

2020-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Vasospasm, Subarachnoid Hemorrhage, Aneurysmal

Keywords

Stellate Ganglion Block, Subarachnoid Hemorrhage, Cerebral Vasospasm, Transcranial Doppler Ultrasonography

Brief summary

To investigate whether the stellate ganglion block is helpful in relieving cerebral vasospasm during aneurysmal coil embolism surgery. The effect was assessed by Transcranial Doppler (TCD).

Interventions

PROCEDUREStellate Ganglion Block

Stellate ganglion block under ultra-guide will be administered using 0.25% ropivacaine 10mL

PROCEDUREPlacebo

Stellate ganglion block under ultra-guide will be administered using 0.9% saline 10mL

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* 1.Emergency patients with subarachnoid hemorrhage caused by ruptured aneurysm, aged 18-65 years; 2. ASA : II-IV grade, Hunt-Hess : I-III grade 3. For the first case, the operation time is within 24 hours. 4.After signing informed consent, underwent interventional intravascular embolization

Exclusion criteria

* 1\. Patients with severe bleeding disorders; 2. Patients with trauma and local infection risk in the nerve block area; 3. Patients with previous aneurysm surgery and unruptured aneurysm; 4. Aneurysm located in middle cerebral artery; 5. Patients with unconsciousness cannot cooperate with the block operation; 6. Those with a history of mental illness and epilepsy; 7. Those who have a history of severe cardiovascular and cerebrovascular diseases and severe organ diseases;

Design outcomes

Primary

Measure	Time frame
The incidence of cerebral vasospasm	Change from baseline at 5day,after subarachnoid hemorrhage

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026